Martell Christopher 4

What Happened Martell Christopher, a director of Candel Therapeutics, was granted a derivative award covering 32,000 shares on 2026-06-23. The Form 4 reports the acquisition as an award (transaction code A) at $0.00 (no cash paid). This is a compensation grant rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-23; Form 4 filed 2026-06-24 (timely filing).
• Award: option/derivative covering 32,000 shares; reported price $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote: Award vests and becomes exercisable upon the earlier of (i) June 23, 2027 or (ii) the next Annual Meeting of Stockholders. Vesting ceases if the reporting person stops serving as a director unless the Board decides otherwise.
• No 10b5‑1 plan, tax withholding, or sale noted in this filing.

Context This is a time‑based equity grant to a board member, which is common for director compensation. Because the award vests in the future and was not exercised or sold, it does not represent an immediate purchase or liquidity event — it simply increases potential future ownership if vesting conditions are met.